Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma

Abstract

Tenarad RIT is effective in chemorefractory HL and resulted in objective responses or clinical benefit in the majority of patients. Toxicity was acceptable despite the high load of prior treatments, previous ASCT and multiple Tenarad administrations. Further studies are planned to define the most effective schedule for this type of RIT in HL patients.

Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation

“…Stromal structures decorated with IL2 were detectable 6 days after the last administration of F16-IL2, indicating that the immunocytokine exhibited on-target persistence times of several days in vivo. In patients with solid tumors, comparable on-target persistence times have been described for vascular-targeting antibodies (29)(30)(31)(32)(33). The lack of posttherapeutic IL2 bone marrow signals in patient 4 might be explained by interindividual differences in targeting performance in vivo.…”

Tenascin-C: Exploitation and collateral damage in cancer management

“…41 A first result on dosage and efficacy was reported recently. 42 In this study, Tenarad was administered to 8 Hodgkin's lymphoma patients that were refractory to conventional treatment. The enrolled patients had excessively been treated with conventional therapies prior to Tenarad that they had received by intravenous injection (2.05 GBq/m2, 5-10 mg).…”

“…Five patients received an additional treatment between 3-12 month after the initial dose in particular upon notice of disease stabilization (reduced number and/or size of lesions) upon the first administration. 42 Altogether, the current antibody based cancer therapeutics targeting tenascin-C have been tested in phase I/II clinical trials for safety, dose and toxicity issues using small patient cohorts. These studies show that these antibodies can be safely administered.…”

From target discovery to clinical trials with armed antibody products

“…The F16 antibody, specific to the alternatively-spliced A1 domain [33], has been moved to clinical investigations, both as fusion protein with IL2 [34] and as a radiolabeled product [35,36]. The A1 domain of fibronectin is broadly expressed in the majority of human malignancies, including lymphomas [37] and acute leukemias [38].…”